RxDoctor Payments Data

Swaraj Bose, MD

Ophthalmology · Orange, CANPI 1285714360

Payments from drug & device makers

$29,237in general payments, 2019–2025

Across 130 payments — averaging $224.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$28K
  • AstraZeneca$589
  • Argenx US, Inc.$147
  • CSL Behring$128
  • Dompe US, Inc.$112
  • AbbVie$72
  • plus $73 from 4 others

What the payments were for

  • Speaking & faculty fees$25,29087%
  • Travel & lodging$9113%
  • Food & beverage$2,86610%
  • Education$1701%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,237 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$444,281
Medicare patients
918
Services billed
8,674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine31$16,787
LumiganBimatoprost37$12,567
Pyridostigmine Bromide106$10,788
Pentoxifylline155$4,090
Cyclosporine23$2,815
Tobramycin-DexamethasoneTobramycin/Dexamethasone66$2,703
Alphagan PBrimonidine Tartrate11$2,007
Brimonidine Tartrate31$1,375
Latanoprost178$1,080
Timolol Maleate29$981
Apraclonidine Hcl16$911
Dorzolamide-TimololDorzolamide/Timolol/Pf12$854
Prednisone98$574
Baclofen18$264
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat17$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$72$31,36179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Orange

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →